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BACKGROUND
• To describe the outcomes of patients with bone-LCH who received bisphosphonate therapy.
• To evaluate whether bisphosphonates can be effective in non-osseous LCH lesions.
• All 18 patients received bisphosphonates therapy either at diagnosis or at ≥ 1st reactivation.
• Patients had either single system (SS) or multisystem (MS) LCH with or without risk organ involvement.
• Patients were treated with Zoledronic acid (n=10), followed by Pamidronate (n=4) and Alendronate (n= 3); one patient received both pamidronate and zoledronic acid.
• All patients reported significant reduction in pain, to either no or mild pain after administration of bisphosphonates, with none having moderate/severe pain.
• 13/18 patients (72%) achieved complete remission (CR) in the bone lesions, including lesions in skin (n=1), lung (n=1) and pituitary (n=1); 2 had partial response and 3 had no response.
• Among the 13 CR patients, 12 had no active disease for a median of 4.1 years (range 2.8 -5.1 years) and 1 developed radiographic neurodegeneration after 2 years.
• Bisphosphonate therapy was well tolerated by all patients with no major toxicity.
• Progression-free survival (PFS) was 75 ± 11% at 3 years, with a trend favoring better PFS (P=0.24) in patients with no or first reactivation compared with those having ≥ 2 reactivations.
• Age, gender, system involvement at diagnosis and concomitant medications did not affect the PFS.
MATERIALS & METHODS
• Retrospective clinical data were collected and analyzed on 18 LCH patients (both pediatric and adult) treated with bisphosphonates from 4 centers world-wide using a standardized data collection sheet.
• Appropriate research ethics approval was obtained from each of the participating centers.
RESULTS
CONCLUSIONS
• This is the largest cohort of LCH patients treated with bisphosphonates in the literature so far.
• Bisphosphonates significantly improved bone pain in patients with bone LCH, and may be effective in treating extra-osseous disease.
• A prospective randomized trial evaluating the role of bisphosphonates in multifocal bone LCH is warranted.
• Langerhans cell histiocytosis (LCH) is characterized by reactive clonal proliferation and accumulation of pathological dendritic cells.
• Bone involvement in LCH can be destructive and painful with significant morbidity from pathologic fractures.
• Bisphosphonates are osteoclast inhibitors that can be effective in treating bone Langerhans cell histiocytosis (LCH).
